Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902)
Gastric Cancer · 2026
DOI: 10.1007/s10120-025-01705-8 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Gastric Cancer, 2026. Verfasst von Shunji Endo und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant Therapy. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Yakult Honsha.
Abstract (Originalsprache)
BACKGROUND: Large type 3 (≥ 8 cm) and type 4 gastric cancers are associated with extremely poor prognoses. The phase III JCOG0501 trial, which evaluated neoadjuvant S-1 plus cisplatin, failed to demonstrate any survival benefits. Docetaxel, oxaliplatin, and S-1 (DOS) have been explored as more effective perioperative regimens for these tumors. METHODS: Eligible patients had large type 3 or type 4 gastric cancer without distant metastases, except for positive peritoneal cytology (CY). Patients received three cycles of neoadjuvant DOS (docetaxel 40 mg/m2, oxaliplatin 100 mg/m2, and oral S-1 at 80 mg/m2/day for 14 days), followed by gastrectomy with ≥ D2 lymphadenectomy and one year of adjuvant docetaxel plus S-1. The primary endpoint was the 3 year progression-free survival (PFS) rate, with an expected value of 60% and a threshold of 45%. A one-sample log-rank test was performed with an α level of 0.10. RESULTS: Of the 48 patients enrolled, 27 had type 4 tumors (56.2%), and 10 (20.8%) had CY1. Overall, 91.7% of patients completed neoadjuvant DOS. R0 resection rate was achieved in 89.6% of patients, a pathological response grade ≥ 1b in 66.7%, and negative CY conversion in 80.0%. The 3-year PFS rate was 37.5% (95% confidence interval [CI], 24.1-50.6%; 80% CI 28.6-46.4%; p = 0.960), and the 3-year overall survival rate was 52.1% (95% CI 37.2-65.0%). CONCLUSIONS: Although neoadjuvant DOS therapy demonstrated favorable pathological responses, the 3-year PFS did not exceed the predefined threshold, and a survival benefit was not demonstrated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Digestive Surgery, Kawasaki Medical School, Kurashiki, Japan.
- Department of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
- Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki City, Osaka, Japan. yamagu.toshifumi@gmail.com.
- Department of Surgery, Osaka Rosai Hospital, Sakai, Japan.
- Department of Surgery, Yao Municipal Hospital, Yao, Japan.
- Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.
ORCID-Profile: Shunji Endo
Förderung
- Yakult Honsha
Zitieren
APA
Endo, S., Tanaka, R., Yamaguchi, T., Miyagaki, H., Kawada, J., Omori, T., Takahashi, N., Masuzawa, T., Furukawa, H., Sato, Y., Takeno, A., Shinno, N., Kawabata, R., Katsuyama, S., Higashi, S., Kurokawa, Y., Tsujinaka, T., Shimokawa, T., & Satoh, T. (2026). Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902). Gastric Cancer. https://doi.org/10.1007/s10120-025-01705-8
Vancouver
Endo S, Tanaka R, Yamaguchi T, Miyagaki H, Kawada J, Omori T, et al. Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902). Gastric Cancer. 2026. doi:10.1007/s10120-025-01705-8
BibTeX
@article{Endo2026,
author = {Endo, Shunji and Tanaka, Ryo and Yamaguchi, Toshifumi and Miyagaki, Hiromichi and Kawada, Junji and Omori, Takeshi and Takahashi, Naoki and Masuzawa, Toru and Furukawa, Haruna and Sato, Yuya and Takeno, Atsushi and Shinno, Naoki and Kawabata, Ryohei and Katsuyama, Shinsuke and Higashi, Shigeyoshi and Kurokawa, Yukinori and Tsujinaka, Toshimasa and Shimokawa, Toshio and Satoh, Taroh},
title = {Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902)},
journal = {Gastric Cancer},
year = {2026},
doi = {10.1007/s10120-025-01705-8}
}
EUVIMED